drugset / Trial / NCT01933919

A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder

NCT01933919

Phase 3 Completed 38 enrolled AbbVie Meiji Seika Pharma Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item from baseline to the last observation visit (10 weeks) in pediatric/adolescent participants with obsessive compulsive disorder (OCD). The objective of the second phase of the study is to evaluate the long-term safety and efficacy of fluvoxamine in pediatric/adolescent patients with OCD.

Timeline

Start
2013-08-14
Primary completion
2015-06-18
Completion
2016-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluvoxamine Unknown 150 mg